From: Methylation of the SPARC gene promoter and its clinical implication in pancreatic cancer
Clinical characteristics | Cases (n = 40) | Methylation ratio (%) | |||||
---|---|---|---|---|---|---|---|
 |  | Region 1 | p | Region 2 | p | Total | p |
Gender | Â | Â | Â | Â | Â | Â | Â |
   Male | 25 | 58.6 ± 11.8 | 0.709 | 53.6 ± 18.7 | 0.265 | 56.5 ± 11.9 | 0.337 |
   Female | 15 | 59.8 ± 12.1 |  | 55.5 ± 22.6 |  | 58.0 ± 13.2 |  |
Age (yrs) | Â | Â | Â | Â | Â | Â | Â |
   ≤ 55 | 19 | 58.0 ± 12.0 | 0.386 | 52.6 ± 19.1 | 0.156 | 55.7 ± 12.1 | 0.142 |
   > 55 | 21 | 60.0 ± 11.7 |  | 56.0 ± 21.0 |  | 58.3 ± 12.6 |  |
Alcohol | Â | Â | Â | Â | Â | Â | Â |
   -- | 20 | 58.7 ± 12.9 | 0.794 | 46.6 ± 18.2 | 0.016 | 53.7 ± 11.2 | 0.154 |
   + | 20 | 60.0 ± 11.7 |  | 62.1 ± 19.1 |  | 60.5 ± 12.6 |  |
Smoking | Â | Â | Â | Â | Â | Â | Â |
   -- | 22 | 58.1 ± 13.7 | 0.671 | 47.5 ± 17.5 | 0.017 | 53.7 ± 11.9 | 0.067 |
   + | 18 | 60.2 ± 9.1 |  | 62.8 ± 19.1 |  | 61.3 ± 11.7 |  |
Tumor size (cm) | Â | Â | Â | Â | Â | Â | Â |
   ≤ 2 | 21 | 55.4 ± 10.5 | 0.087 | 46.1 ± 18.8 | 0.029 | 51.5 ± 10.1 | 0.013 |
   > 2 | 19 | 63.1 ± 12.0 |  | 63.5 ± 17.4 |  | 63.3 ± 11.7 |  |
Differentiation | Â | Â | Â | Â | Â | Â | Â |
   Moderate | 19 | 59.6 ± 12.2 | 0.625 | 53.6 ± 20.4 | 0.799 | 57.1 ± 12.4 | 0.877 |
   Poor | 21 | 58.6 ± 11.6 |  | 55.0 ± 20.1 |  | 57.1 ± 12.5 |  |
Lymph node metastasis | Â | Â | Â | Â | Â | Â | Â |
   -- | 23 | 60.4 ± 12.4 | 0.307 | 53.7 ± 20.0 | 0.832 | 57.6 ± 12.5 | 0.421 |
   + | 17 | 57.2 ± 10.9 |  | 55.2 ± 20.7 |  | 56.4 ± 12.3 |  |
pTNM stage | Â | Â | Â | Â | Â | Â | Â |
   I+II | 21 | 58.2 ± 12.4 | 0.444 | 51.9 ± 20.1 | 0.867 | 55.5 ± 12.6 | 0.543 |
   III+IV | 19 | 60.0 ± 11.2 |  | 57.1 ± 20.0 |  | 58.8 ± 12.0 |  |